Chemistry:Gemopatrilat

From HandWiki
Revision as of 21:22, 5 February 2024 by Rtextdoc (talk | contribs) (correction)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Short description: Chemical compound
Gemopatrilat
Gemopatrilat.svg
Clinical data
Other namesBMS-189921
ATC code
  • None
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H26N2O4S
Molar mass378.49 g·mol−1
3D model (JSmol)

Gemopatrilat (INN)[1] is an experimental drug that was never marketed.[2] It acts as a vasopeptidase inhibitor.[3][4] It inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (neprilysin).[5]

References

  1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 46". World Health Organization. p. 200. https://www.who.int/medicines/publications/druginformation/innlists/RL64.pdf. 
  2. "Gemopatrilat". AdisInsight. http://adisinsight.springer.com/drugs/800009581. "Highest Development Phases: Discontinued" 
  3. "Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes". Kidney International 63 (1): 64–71. January 2003. doi:10.1046/j.1523-1755.2003.00708.x. PMID 12472769. https://www.kidney-international.org/article/S0085-2538(15)48845-3/fulltext. 
  4. "Metabolism of [14C]gemopatrilat after oral administration to rats, dogs, and humans". Drug Metabolism and Disposition 34 (6): 961–70. June 2006. doi:10.1124/dmd.105.007500. PMID 16540589. 
  5. "In-vitro and in-vivo inhibition of rat neutral endopeptidase and angiotensin converting enzyme with the vasopeptidase inhibitor gemopatrilat". Journal of Hypertension 19 (5): 941–6. May 2001. doi:10.1097/00004872-200105000-00015. PMID 11393678.